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ABSTRACT
Alzheimer’s disease (AD) is a neurodegenerative disorder that starts slowly, progressively leads to death and contributes to about 60-70% cases of 
dementia. AD is characterized with senile plaques (SPs) and neurofibrillary tangles (NFTs), and the major symptoms include problems with language, 
dis-orientation of words, unable to manage self-care, memory loss, and behavioral issues which gradually lead to completely lose bodily functions later. 
The actual cause for the disease is not known until date. Recent research shows distinct paths that closely try to reveal various cytoplasmic, genetic, 
behavioral, environmental, and epigenetic causes that may lead to the development of AD. Most likely all studies target the SPs, protein fragments 
called β-amyloid and NFTs, twisted fibers of a protein called tau. Since the exact causative mechanism is not yet clearly understood, ultimately finding 
a suitable treatment or management for the disease has also become an ominous challenge for researchers.
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INTRODUCTION
Alzheimer’s disease (AD) was first defined and described by 
Alois Alzheimer, a German psychiatrist and pathologist [1] at the 
37th Conference of South-West German Psychiatrists in Tübingen, 
Alzheimer described his patient August D, a 51-year-old woman 
from Frankfurt showing symptoms of progressive cognitive 
impairment, focal symptoms, hallucinations, delusions, and 
psychosocial incompetence. Plaques, neurofibrillary tangles (NFTs), 
and arteriosclerotic changes were found under the observation 
of necropsy. The word Alzheimer was originally used to refer 
pre-senile dementia; later it was used to describe the largest cause 
of primary dementia—senile dementia of the Alzheimer type [2]. AD 
is also known as just Alzheimer’s, is a chronic neurodegenerative 
disease that gradually starts and gets worse over the course of 
time. It is the cause of 60-70% of cases of dementia* (*dementia is 
a general term for loss of memory and other cognitive abilities that 
are serious enough to interfere with the daily activities of life) [3]. 
Approximately, more than 24 million people worldwide are suspected 
to have dementia out of which most of them are thought to have AD. 
This includes about 11% of individual aged 65 and older and one-
third of those who are 85 and older. It is also thought impact more 
than 15 million family members, friends, and caregivers. The most 
common early symptom is difficulty in remembering recent events. 
As the disease advances, the symptoms may include problems with 
language, dis-orientation of words, mood swings, loss of motivation, 
unable to manage self-care, and behavioral issues. Gradually, bodily 
functions are lost, ultimately leading to death. Although the speed 
of progression can vary, the average life expectancy following the 
diagnosis is nearly to last for 3-9 years only. During such conditions, 
people often withdraw from their family and society. The main causes 
of AD are still not well understood [4]. Most experts strongly believe 
that the destruction and death of nerve cells cause memory failure, 
personality changes, problems in carrying out daily activities, and 
other symptoms which further lead to the disease.
NEUROPATHOLOGY OF AD
The brain is composed of more than 100 billion nerve cells (neurons). 
Each nerve cell connects too many others to form communication 
networks. In addition to nerve cells, the brain includes cells specialized 
to support and nourish other cells. Some groups of nerve cells have 
special jobs such as thinking, learning and memory and some help us 
see, hear, smell and tell our muscles when to move. Brain cells operate 
like tiny factories. They receive supplies, generate energy, construct 
equipment and get rid of waste. Cells also process and store information 
and communicate with other cells. Keeping everything running 
requires coordination as well as large amounts of fuel and oxygen. 
Scientists believe that AD prevents certain parts of a cell’s factory from 
functioning well, but they are not sure where the actual trouble starts. 
But just like a real factory, backups and breakdowns in one system cause 
problems in other areas. Similarly, in the brain the damage spreads and 
cells lose their ability to function and eventually die. Individuals with 
Alzheimer’s have loads of plaques and tangles in the brain. Plaques 
are clumps of protein fragments called β-amyloid (Aβ) that occurs in 
the spaces between nerve cells. Tangles are twisted fibers of a protein 
called tau that buildup inside cells. Although autopsy studies show that 
most people develop some plaques and tangles as they age, those with 
AD tend to develop far more and in a predictable pattern, beginning 
in the areas important for memory before spreading to other regions. 
AD is characterized by the development of senile plaques (SPs) and 
NFTs, which are associated with neuronal destruction mostly occurring 
in the cholinergic neurons [5]. The actual role of plaques and tangles 
in AD is not yet known. Aβ plaques or SPs are clumps of insoluble 
peptides that result from the proteolytic cleavage of Aβ precursor 
protein (APP - the exact function of which is not known) and is found 
in extracellular deposits throughout the central nervous system (CNS). 
The APP is normally cleaved by three enzymes β-secretase, α-secretase, 
γ-secretase, respectively. Cleavage by the β-secretase followed by 
the γ-secretase yields a 40-amino acid peptide. In AD individuals, the 
variant of γ-secretase cleaves APP at the wrong position yielding a 
39-42 amino acid peptide called Aβ42 or Aβ, which is insoluble and 
aggregates as identical clumps of peptides termed the Aβ plaques. Aβ is 
thought to interfere with neuronal function due to its stimulatory effect 
on free radical production resulting in oxidative stress and neuronal 
cell death. NFTs are paired helical filaments composed of tau protein 
which in normal cells are essential for axonal growth and development. 
These when hyperphosphorylated, the tau protein form tangles that are 
systematically deposited within neurons located in the hippocampus 
and medial temporal lobe, the parieto-temporal region, and the frontal 
association cortices leading to cell death [6].
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The discovery of Aβ as the most important molecular constituent of 
the Senile plaques resulted in the formulation of the “amyloid cascade 
hypothesis” (ACH). ACH synthesizes histopathological and genetic 
information and posits that the deposition of the Aβ peptide in the 
brain parenchyma initiates a sequence of events that ultimately lead to 
AD dementia. Autosomal dominant mutations that cause early onset in 
familial AD occur in three genes: Presenilin 1 (PSEN1), PSEN2, and APP, 
respectively. This hypothesis has been modified over the years after various 
observations and studies and it has become clear that the correlation 
between dementia or other cognitive alterations and accumulation of Aβ 
in the brain in the form of amyloid plaques is not linear or stable, neither 
in humans [7] nor in mice [8]. Although Aβ-centric approaches contribute 
more to the research background, all that which reached Phase III clinical 
trials have failed for various drug based studies [9].
The limitations for the ACH include two major objectives; first, 
senile plaques and NFTs may be reactive products resulting from 
neurodegeneration in AD rather than being the cause for the 
disease [10], and second, there are not any general mechanism accepted 
to explain how the deposition of Aβ leads to the formation of NFTs.
CAUSES OF AD
AD involves the failure of nerve cells but it is still unknown why this 
dysfunction happens. However, certain risk factors which play a role in 
increasing the chances of developing AD have been identified.
AGE
The greatest known risk factor for Alzheimer’s is increasing age. One 
in nine individuals of 65 and older age groups and nearly one-third 
of the total population with 85 and older age groups are increasingly 
subjected to AD.
FAMILY HISTORY
Research has illustrated that those individuals who have a twin, parent, 
brother, or sister with Alzheimer’s are more likely to develop the 
disease than individuals who do not and not all members of the family 
acquire the disease.
FAMILIAL ALZHEIMER’S AND GENETICS
Two categories of genes influence a person to develop a disease 
normally: The risk genes and deterministic genes. Risk genes increase 
the likelihood to develop a disease but do not assure it will happen. 
Deterministic genes directly serve as the cause of the disease, assuring 
that anyone who inherits will develop that disease or disorder.
Researchers have found several genes that increase the risk of 
Alzheimer’s. Some strong evidence shows that the Apolipoprotein E 
(ApoE) gene on chromosome 19 has gained much recent attention 
and it has been the first risk gene identified for AD. ApoE is a protein 
modulator of phospholipid transport that may have a role in synaptic 
remodeling. The common forms of the APOE gene are APOE-e2 and 
APOE-e3. A copy of APOE gene is inherited to the offspring from each 
parent and those who inherit a single copy of the APOE-e4gene have 
increased risk of developing AD and those who inherit both the copies 
of the gene are at an even higher risk, but not always. The postulated 
mechanisms of APOE-e4 include amyloid deposition and abnormal tau 
phosphorylation, a major component of NFTs.
Rare deterministic genes cause Alzheimer’s in a few hundred extended 
families worldwide. These genes are estimated to account for <1% of 
cases. Individuals with these genes usually develop symptoms in their 
40s or 50s.
OTHERS
Phosphatase and tensin (PTEN)
Homolog PTEN a dual-function phosphatase that possesses both lipid 
and protein phosphatase activities through its lipid phosphatase action 
(i.e., by hydrolyzing the crucial lipid secondary messenger PI (3,4,5) 
P3 to PI (3,4) P2 [11] inhibiting cell survival responses to PI3-kinase 
and Akt [12]. PTEN has been shown to modulate cell migration, growth, 
survival, and apoptosis and plays its major role as a tumor suppressor. 
More recent studies have shown that PTEN is expressed in neurons 
in human, mouse and rat brain [13-15] and suggest a functional role 
for PTEN in CNS development. PTEN is one of the major regulators of 
proliferation in neural stem cells and regulates neuronal migration, 
differentiation, soma size, and apoptosis. PTEN also negatively 
regulates insulin signaling. PTEN is also known to be a negative 
regulator of insulin resistance in peripheral tissues such as skeletal 
muscle and adipose tissue, where its down-regulation improves insulin 
sensitivity [16]. Akt is a vital promoter of neuronal survival in AD. 
PI3-kinase/Akt activation prevents Aβ-induced neurotoxicity in cells. 
Akt inhibits the enzyme glycogen synthase kinase 3 (GSK-3), which is 
thought to play a dual role in the regulation of both Aβ production and 
tau phosphorylation. PTEN by inhibiting Akt increases GSK-3 activity 
in cells and would promote tau and Ab pathologies via the signaling 
mechanism. Some researchers suggest that the gene encoding PTEN 
locates to the region of chromosome 10 linked to late-onset AD [17], 
further showing that it plays a functional role for PTEN in disease 
development. Several studies have reported that increases in Akt 
activity in AD brain [18,19], and more recent observations show that 
this may be due to reductions in PTEN levels [20].
MITOCHONDRIAL DYSFUNCTION
Aβ is considered as a potential mitochondrial poison that affects the 
synaptic pool. In individuals carrying AD, exposure to Aβ will inhibit 
certain mitochondrial enzymes like cytochrome C in the brain. The 
accumulation of Aβ in damaged mitochondria of AD individuals can be 
found intra-neuronally in the brain [21].
CELL-CYCLE RE-ENTRY
Many scientists hypothesized that the failure in the normal suppression 
of cell cycle as one of the reasons for the onset of AD [22]. Bio-markers 
of cell-cycle re-entry especially in G1-S-phase boundary can be detected 
in all stages of AD and even in mild cognitive impairment [23,24].
CALPAIN-CATHEPSIN HYPOTHESIS
Autophagic vacuoles or granulovacuolar degenerations can be seen 
in degenerating neurons of AD patients. This probably is a causative 
connection between neuronal death and autophagy failure. Many 
scientists proposed that an age-dependent oxidative stress affects 
autophagic-lysosomal system through cleavage and carbonylated 
heat-shock protein 70.1 (Hsp70.1). Membrane lipids are vulnerable to 
the oxidative stresses, and they generate toxic peroxidation products 
that can carbonylated Hsp70.1. Many evidence suggests that Hsp70.1 
is a molecular chaperone which repairs damaged proteins and 
maintains lysosomal integrity. Impairments of lysosomal functions 
and stabilization are found to be driven by calpain-mediated cleavage 
of carbonylated Hsp70.1, which results in lysosomal permeabilization 
or rupture releasing the cell degradation enzymes, cathepsins which 
eventually lead to the AD. This hypothesis is called as calpain-cathepsin 
hypothesis, which is recently put forward by the scientists and currently 
most acceptable [25].
DIAGNOSIS OF AD
Diagnosing Alzheimer’s requires careful medical evaluation, including 
a thorough medical history, mental status testing, a physical and 
neurological exam. Magnetic resonance imaging (MRI), computed 
tomography (CT), single photon emission CT, and positron emission 
tomography which can be used in the determining cerebral pathology 
in AD patients. Chronic cerebrospinal venous insufficiency has been 
evaluated using echo color Doppler (ECD), ultrasound Doppler, 
ultrasound Doppler sonography, transcranial color-coded sonography, 
and even MRI. Application of ECD technique to detect neurodegeneration 
can be used to find AD in patients. During a neurological examination, 
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the problems that signal brain cells to cause disorders other than 
Alzheimer’s will be evaluated. The doctor will look for signs of small 
or large strokes, Parkinson’s disease, brain tumors, fluid accumulation 
on the brain, and other illnesses that may impair memory or thinking.
AD MANAGEMENT
Numerous studies have assessed factors that may affect the 
incidence of AD, and many prominent studies have shown the closest 
association of the disease, but they have not proven the relationship 
and it is still not clear whether it would reduce the risk of severity 
of the AD. Certain epidemiological factors of AD are associated with 
dietary habits, cardiovascular diseases, and intellectual activities. 
Presently, AD medications target only secondary risk factors such as 
hypercholesterolemia, hypertension, and smoking and very few drugs 
have shown little success to arrest the progression of AD.
Hormone replacement therapy has also been proposed for treating AD, 
but many researchers suggested that it still increases dementia. Change 
in lifestyle of AD patients is recommended for a possible management 
strategy of AD. Some research papers also suggest that caffeine, tea, red 
wine, cocoa, Vitamin A, C, E, folic acid and minerals such as selenium 
and Zinc are effective against AD management.
Acetylcholinesterase inhibitors are first-line agents for the treatment 
of mild to moderate AD, per existing guidelines. Acetylcholinesterase 
inhibitors reversibly bind and degrade acetylcholine which is 
involved in memory by inactivating the enzyme [27]. A N-methyl-D-
aspartate (NMDA) receptor antagonist memantine prevents excessive 
glutamatergic activity. The Cochrane review showed the memantine 
activity at 20 mg/day dosage for 6 months would slightly improve 
the ability to do activities of daily living and cognition in patients with 
moderate to severe AD. Selegiline (Eldepryl) is a monoamine oxidase 
type B inhibitor with minimal anticholinergic effects. Currently, there 
is not much evidence to recommend selegiline for the treatment of AD. 
Antipsychotics are not approved by the Food and Drug Administration 
for the treatment of AD, though they are commonly used to treat 
behavioral symptoms. Evidence suggests that olanzapine (Zyprexa) and 
risperidone (Risperdal) reduce aggression, and risperidone reduces 
psychosis in patients with AD [28]. The other potential treatments for 
AD include resveratrol, a compound from the skin of red grapes that may 
have beneficial effects on aging, a NMDA receptor antagonist that may 
also weakly inhibit acetylcholinesterase, which in turn may improve 
cognitive performance of the affected individual and is currently in 
testing process of phase 3 trials.
A recent consensus statement from the National Institutes of Health’s 
State-of-the-Science Conference on Preventing AD and cognitive decline 
concluded that the current evidence is insufficient to support the 
association of any modifiable factor, pharmacologic agent, or dietary 
supplement with a reduction in the risk of AD [29]. The recent updates 
on the advances in treating AD include the Anti-amyloid therapy involves 
the usage of drugs with variant actions on different mechanisms for 
example: Enhance the clearance of Aβ, reduce the production of Aβ 
and inhibit the accumulation of Aβ; γ-secretase inhibitors (GSI) and 
modulators; using kinase inhibitors to decrease the activity of kinase 
enzyme the interaction between GSK3ββ and protein phosphate 2 
(PP2A) increases the tau hyper-phosphorylation and NFT generation; 
therapy for mitochondrial dysfunction; anticholinergic therapy by the 
administration of choline inhibitors [30].
CONCLUSION
AD pathogenesis appears to be initiated by the production, accumulation 
and oligomerization of Aβ protein (Aβ), forming extracellular amyloid 
plaques that lead to neuropathological signs of the disease including 
tangles of intracellular hyperphosphorylated tau, gliosis, synaptic 
dysfunction and eventually cell death. This neurodegeneration 
association with AD starts many years before the clinical onset, during 
this preclinical phase the plaque and tangle increase in the brain until a 
threshold level is reached and beyond which the cognitive impairment 
become manifested. Different regions of the brain show differential 
vulnerability to AD, with some regions being particularly affected 
and others relatively resistant, both plaques and tangles occur first 
in the areas of the brain involved in learning, memory, and emotional 
behaviors. Other areas such as the cerebellum have relatively high 
resistant to the neuronal damage with little or no tangle and plaque 
formation, tau pathology or neuronal loss. Epigenetic mechanisms show 
a wide range of important cognitive and neurobiological processes 
in the brain such as neurogenesis and brain development, neuronal 
activity, learning and memory, and circadian rhythm and disruption to 
these processes is likely to play a profound role in health and disease. 
Several epidemiological and clinical features of AD suggest an epigenetic 
contribution and these include monozygotic twin discordance in both 
AD diagnosis by Plomin et al., 1994 [31]; evidence of parent-of-origin 
effects in both disease transmission by Edland et al., 1996 [32] and 
genetic association studies by Bassett et al., 2006 [33]. Recent literature 
shows that there are striking age-associated epigenetic changes in the 
human brain including within the APP and microtubule-associated 
protein tau genes.
The causes that contribute to AD are potentially observed by various 
studies; on the other hand, many potential therapeutic agents are 
currently under investigation for the treatment and management 
of AD. APP and the enzymes involved in Aβ formation are thought to 
contribute much to the genetic forms of the disease. The methods to 
Medication* Usage Adverse effects (%) General dosage
Acetyl cholinesterase 
inhibitors
Nausea, vomiting, and diarrhoea; 
cardiovascular and neurologic 
adverse effects
Donepezil (aricept) Approved for use in all stages 
of AD
Adverse effect (15.1-71.3) 10 mg/day
Galantamine (razadyne) Moderate to severe stage of AD Adverse effect (31.9-55) 8 mg twice per day, or 16 mg extended 
release formulation once per day
Rivastigmine (exelon) Moderate to severe stage of AD Adverse effect (20.1-78) 6 mg orally twice per day or 9.5 mg/24 hrs 
patch
Tacrine (cognex) Tacrine is no longer available because of safety and tolerability concerns
NMDA receptor 
antagonist
Dizziness, confusion, headache, 
diarrhoea, vomiting
Memantine (namenda) Moderate to severe stage of AD Adverse effects and dropout rates not 
statistically different from placebo
10 mg twice per day
Monoamine oxidase 
type B inhibitor
Selegiline There is not enough evidence to recommend selegiline for the treatment of AD
NMDA: N-methyl-D-aspartate, *medications do not reverse the symptoms of dementia but may slow their course, AD: Alzheimer’s disease
Table 1: Medications for AD [26]
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reduce amyloid plaque severity, by altering the amyloid metabolism 
are being evaluated in the recent studies. Immunotherapy to promote 
the clearance of Aβ from the CNS is being assessed gradually. The PTEN 
can be assessed as the new potential target for the prevention of AD. 
In addition to the varied role of insulin in peripheral tissues, it has 
profound effects in the CNS, where it regulates various key physiological 
functions such as energy homeostasis, food intake, reproductive 
endocrinology, peripheral insulin actions, sympathetic activity and 
even memory, and learning [34]. Dysfunction of the insulin-signaling 
pathway in the CNS has been contributing to several pathophysiological 
conditions, including hyperphagia, obesity, and type 2 diabetes. To add 
on to these complications, there is a wide recognition that impaired 
insulin signaling and glucose metabolism in the brain acts as a mediator 
of chronic neurodegenerative disease AD. The molecular mechanism of 
insulin resistance in neurons is largely unknown. In peripheral tissues, 
such as skeletal muscle, liver, and adipose the drug development to 
treat neuronal insulin resistance is non-productive. PTEN and Src 
homology 2 domain contain inositol 5′ phosphatase 2 (SHIP2) and 
have been widely suggested as the negative regulators of insulin/PI3K 
signaling [35]. There is a large recognition that impaired insulin actions 
in the brain act as mediators of AD and thus AD is also characterized 
as a brain-specific form of diabetes. AD is termed as “type 3 diabetes” 
and has been proposed by Steen et al. in 2005 [36]. Although there is 
growing wealth and knowledge on the data on the backgrounds of AD, 
it has not been enough to present a single or cohesive picture about 
its causes nor the treatments till date. In the most recent technology, 
molecular docking studies are performed to detect the molecular 
interactions, active site prediction, and drug interaction based studies; 
these advanced techniques make help in the better understanding of 
molecular basis of AD [37].
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